About the Company
Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AXGT News
7 Best Gene-Editing Stocks to Invest in Right Now
Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and can ...
Gene therapy maker bluebird to revise financials after accounting errors
March 26 (Reuters) - Gene therapy maker bluebird bio (BLUE.O), opens new tab said on Tuesday it plans to revise its financial statements for 2022 and the first three quarters of last year due to ...
Gene Therapy News
Promising New Gene Therapy Approach for Genetic Heart Disease: Clinical Trials Imminent Dec. 7, 2023 — Researchers have laid the foundation for the development of a gene therapy for the genetic ...
Gene Therapy: Non-Viral Vectors
I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal. In this subseries, we focus specifically on ...
Gene Therapy Methods Explained
I include a full spectrum of chemical, gene, and protein-based medicines, cell-based therapies, and biomechanical interventions that achieve that goal. In this subseries, we focus specifically on ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, April 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for ...
Is Gene Therapy Nearing a Tipping Point?
Gene therapy has undergone a renaissance in recent years, with several drugs offering beneficial, even life-saving treatments, now approved by the FDA. One example was reported earlier this year ...
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
Gene and cell therapies have been popular topics over the years at the Academy of Managed Care Pharmacy (AMCP) annual meeting. At this year’s event, presenters took the stage on April 17 to ...
Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight
According to DelveInsight's analysis, the growth of the gene therapies market in ophthalmology is expected to be mainly driven by the increasing prevalence of eye disease, rise in awareness and ...
Megatrends: Gene Therapy and Editing
Investors often like to be on the cutting edge of new developments, and it doesn't get much more cutting edge than gene therapy and editing. The ability to make changes to a person's DNA – the ...
Gene Therapy for Parkinson's Disease
Expert Rev Neurother. 2013;13(6):695-705. Gene therapy using neurotrophic factors is the most promising disease-modifying approach for Parkinson's disease. The strong safety profile and rapidly ...
Cystic Fibrosis Gene Therapy: Successes, Failures and Hopes for the Future
Uta Griesenbach, Eric W.F.W. Alton, Department of Gene Therapy, Faculty of Medicine at the National Heart and Lung Institute, Imperial College London, Manresa Road, London SW3 6LR, UK. E-Mail ...
Loading the latest forecasts...